首页华领医药是一家立足中国，针对全球糖尿病患者尚未满足的临床需求，研发全球原创新药的生物技术公司。华领医药汇聚全球高端人才和科技资源，以国际顶级生物医药投资团队为依托，成功实现了全球首创糖尿病新药Dorzagliatin（HMS5552）在中国完成药品可开发性临床验证，率先进入注册性临床试验阶段。公司已在中国开展2个III期临床试验，分别针对新发未经治疗的和二甲双胍治疗失效的2型糖尿病患者人群。公司将启动药品生命周期管理相关临床试验，并拓展糖尿病个性化治疗和管理的先进理念，联合中国和美国糖尿病领域专家，实现对糖尿病和代谢性疾病及其并发症的有效控制。
Location: China, Shanghai
Total raised: $302.4M
Investors 5
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | F-Prime Ca... | fprimecapi... |
| - | Ally Bridg... | ally-bridg... |
| - | 6 Dimensio... | 6dimension... |
| - | Eight Road... | eightroads... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 19.09.2018 | IPO | $110M | - |
| 27.03.2018 | Series D | $117.4M | - |
| 22.04.2016 | Series C | $50M | - |
| 09.01.2015 | Series B | $25M | - |
Mentions in press and media 16
| Date | Title | Description |
| 03.03.2026 | Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China | First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) management Hong Kong will serve as Hua Medicine's launchpad for international market expansion SHANGHAI a... |
| 28.08.2025 | Hua Medicine Announces 2025 Interim Results | Sales of HuaTangNing (华堂宁®) increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, ... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 24.10.2024 | Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award" | SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- The 17th "C.C. Tan Life Science Award" ceremony was held in Shenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the "C.C. Tan ... |
| 22.04.2021 | HUA MEDICINE (SHANGHAI) LTD. Hua Medicine Shanghai : Environment, Social and Governance Report 2020 | (Incorporated in the Cayman Islands with limited liability) Stock Code: 2552 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2020 CONTENTS 02 ABOUT THE REPORT Compilation Reference Report Scope Report Availability 03 ABOUT US Message from CEO B... |
| 25.08.2020 | STAT China: Two more Hong Kong IPO filings, and Beijing’s latest drug price cuts | A version of this digest first appeared in the weekly STAT China newsletter. To receive future editions, sign up here. Happy Tuesday and welcome back to STAT China. In this edition, two more Hong Kong IPO filings, Beijing’s latest drug pric... |
| 19.09.2018 | Ally Bridge Portfolio News – Hua Medicine Raises $110mn in Hong Kong IPO | SEP 14, 2018 | BioCentury Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the lo... |
| 27.03.2018 | Hua Medicine Raises $117.4 Million in Series D & Series E Financing | - |
| 27.03.2018 | Shanghai drugmaker Hua hauls in $117M megaround, with plans for hefty Hong Kong IPO | A diabetes drugmaker recently rumored to be planning a massive Hong Kong IPO has raised a $117 million mega-round with backing from some of the biggest investors in both China and the US. Hua Medicine said the new influx of ... |
| 27.03.2018 | Hua Medicine Raises $117.4 Million in Series D & Series E Financing | - |
Show more